Gamida Cell Ltd. - Ordinary Shares (GMDA): Price and Financial Metrics
GET POWR RATINGS... FREE!
GMDA Stock Price Chart Interactive Chart >
GMDA Price/Volume Stats
| Current price | $1.73 | 52-week high | $6.84 |
| Prev. close | $1.75 | 52-week low | $1.71 |
| Day low | $1.71 | Volume | 73,793 |
| Day high | $1.76 | Avg. volume | 774,934 |
| 50-day MA | $2.29 | Dividend yield | N/A |
| 200-day MA | $3.13 | Market Cap | 102.42M |
Gamida Cell Ltd. - Ordinary Shares (GMDA) Company Bio
Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
Latest GMDA News From Around the Web
Below are the latest news stories about Gamida Cell Ltd that investors may wish to consider to help them evaluate GMDA as an investment opportunity.
Emergent's (EBS) Q4 Earnings & Sales Beat, CDMO View CutEmergent's (EBS) fourth-quarter 2021 earnings and sales beat estimates. The company lowers its guidance for 2022 CDMO services revenues and adjusted net income. |
BioMarin (BMRN) Q4 Earnings Top Estimates, Sales Fall Y/YBiomarin Pharmaceutical's (BMRN) fourth-quarter earnings and sales beat estimates. Stock declines |
Allogene (ALLO) Beats on Q4 Earnings, Resumes Clinical StudiesAllogene (ALLO) beats earnings estimates for the fourth quarter. However, the stock declines in after-market trading. All clinical studies have been resumed following the removal of clinical hold last month. |
5 Drug/Biotech Stocks Set to Outpace Q4 Earnings EstimatesLet us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings. |
Esperion (ESPR) Q4 Earnings Beat, Product Sales Rise 49%Esperion Therapeutics (ESPR) reports solid fourth-quarter results, beating estimates for earnings and sales. Stock surges. |
GMDA Price Returns
| 1-mo | N/A |
| 3-mo | -58.31% |
| 6-mo | -31.89% |
| 1-year | -73.75% |
| 3-year | -65.94% |
| 5-year | N/A |
| YTD | -31.89% |
| 2021 | -69.73% |
| 2020 | 95.12% |
| 2019 | -56.74% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...